Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is an oral, direct-acting, reversible P2Y12 platelet inhibitor.
## Primary Indications
* In combination with aspirin and other antiplatelet agents, for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
## Adult Dosing
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily for up to 12 months in ACS patients. After 12 months, consider continuing ticagrelor 60 mg twice daily.
* **Maintenance Dose (History of MI):** 60 mg orally twice daily.
## Pediatric Dosing
* Ticagrelor is **not recommended** for use in pediatric patients due to a lack of established efficacy and safety data.
## Dose Adjustments
* No specific dose adjustments are recommended for patients with hepatic or renal impairment.
## Contraindications
* Active pathological bleeding.
* History of intracranial hemorrhage.
* Hypersensitivity to ticagrelor or any of its components.
## Adverse Effects
* **Common:** Dyspnea, bradycardia, diarrhea, contusion, rash.
* **Serious:** Bleeding (major and minor), ventricular pauses, hyperkalemia, angioedema.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Strong inhibitors (e.g., ketoconazole, clarithromycin) can increase ticagrelor exposure and bleeding risk. Strong inducers (e.g., rifampin, phenytoin) can decrease ticagrelor exposure and efficacy.
* **Aspirin:** Concurrent use increases bleeding risk.
* **Other Antiplatelets/Anticoagulants:** Concurrent use significantly increases the risk of bleeding.
* **Statins:** Concurrent use with simvastatin or atorvastatin may increase statin exposure.
## Monitoring
* Monitor for signs and symptoms of bleeding.
* Monitor for dyspnea.
* Consider periodic monitoring of potassium levels, especially in patients with risk factors for hyperkalemia.
## Clinical Pearls
* Ticagrelor has a rapid onset of action and is reversible, unlike clopidogrel.
* Dyspnea is a common side effect and may require discontinuation if severe.
* Discontinue ticagrelor at least 5 days before elective surgery.
* The benefits of ticagrelor 90 mg twice daily in ACS patients generally outweigh the risks for up to 12 months. Long-term use beyond 12 months at 60 mg twice daily should be considered on an individual basis.
***
*Please consult the most current prescribing information and relevant clinical guidelines for complete and up-to-date information.*
